Feasibility of electronic brachytherapy in cervix cancer–A dosimetric comparison of different brachytherapy techniques

Lozares, S.; González-Pérez, Víctor; Pellejero-Pellejero, Santiago; Rodriguez-Ruiz, Lucia; Guinot-Rodriguez, Jose Luis; Villafranca-Iturre, Elena; Méndez-Villamón, Agustina; Gandía-Martínez, Almudena; Fuentemilla-Urío, Naiara; Ruggeri, R.

doi:10.1016/j.brachy.2022.01.006

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latest article on EBT for cervical cancer was published in 2022 and offers an analysis of 48 EBT treatment plans of patients who were previously treated with 192 Ir by an Utrecht type applicator [ 38 ]. This is the first study that includes patients with stage III and stage IV carcinoma which usually require interstitial needles for better target coverage.…”

Section: Discussionmentioning

confidence: 99%

Electronic brachytherapy for gynecological cancers — a systematic review

Hitova-Topkarova

Payakova

Kostova-Lefterova

et al. 2023

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

Background The purpose of this manuscript is to provide an in-depth literature review of the management of endometrial and cervical cancers with electronic brachytherapy. Materials and methods An extensive literature search was performed and 9 articles were selected based on preset criteria. Results The reviewed studies provided dosimetric and clinical results. Patient populations were diverse and prescribed doses varied. When treatment plans were compared to those using cobalt 60 ( 60 Co) and iridium 192 ( 192 Ir) sources researchers found lower or equivalent doses in organs at risk while the doses at the applicator surface were significantly higher for electronic brachytherapy. In the eligible studies, a total of 72 patients received treatment with AxxentXoft vaginal applicator, 29 were treated with the Intrabeam vaginal applicator, and 8 with AxxentXoft cervical applicator. Conclusions All authors found that electronic brachytherapy was safe and well tolerated as higher mucosal doses did not present as adverse clinical effects. Electronic brachytherapy for gynecological cancers has the potential to achieve equivalent tumor control while minimizing bowel and urinary toxicity thus improving the quality of life. More clinical data is needed to stratify patients who would benefit the most.

show abstract

Section: Discussionmentioning

confidence: 99%

Electronic brachytherapy for gynecological cancers — a systematic review

Hitova-Topkarova

Payakova

Kostova-Lefterova

et al. 2023

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

show abstract

“…While the benefit of BT in definitive radiotherapy of LACC is undeniable, there have been major differences in its’ implementation, including low-dose-rate (LDR), high-dose-rate (HDR), and pulsed-dose-rate (PDR) BT. A new possibility with a lower price is electronic brachytherapy, but its’ disadvantage is the lack of compatibility with interstitial needles [ 5 ]. HDR-BT is the most common modality applied in BT today.…”

Section: Purposementioning

confidence: 99%

The impact of different treatment protocols on achieved radiation doses of high-dose-rate brachytherapy for locally advanced cervical cancer: a comparison between 2 fractions in 1 application and separate applications for each fraction

Jääskeläinen¹,

Anttila²,

Palmgren³

et al. 2022

jcb

View full text Add to dashboard Cite

Purpose: To compare radiation doses achieved by image-guided brachytherapy for locally advanced cervical carcinoma implemented with two different protocols.Material and methods: Medical records of 117 patients with locally advanced cervical carcinoma treated with brachytherapy from 2009 to 2018 at our institution were retrospectively reviewed. All patients had received previous external beam radio/chemotherapy. We performed magnetic resonance image-guided adaptive high-dose-rate brachytherapy delivered by intra-cavitary/interstitial applicators. Dose prescription was 7 Gy for four fractions within two weeks. Original schedule of brachytherapy was two fractions delivered on consecutive days with one applicator insertion; this process was repeated one week later (group 1, 54 patients). From 2015 onwards, another protocol of brachytherapy was mainly used, separately performing applicator insertions for each of the four administered fractions (group 2, 63 patients).Results: The high-risk clinical target volume (HR-CTV) D 90 planning aim (PA) of ≥ 85 Gy (hard constraint) was not achieved in 9 cases out of 54 (17%) in group 1 compared with only 2 out of 63 cases (3%) in group 2 (p = 0.022). A difference between the two groups was also found in the fulfillment of PA 90 Gy (soft constraint) (p = 0.027). We conducted a sub-group analysis of target volume groups and observed that the differences were most pronounced with very large tumors (> 50 cm 3 ). In these patients, PA 85 Gy was only fulfilled in 67% cases when treatment involved two applications, but in all cases with four separate applicator insertions (p = 0.010).Conclusions: In our experience, by performing an applicator insertion for each of the fractions, it is possible to correct the non-optimal position of the applicator immediately, and to deliver better doses for consecutive fractions. As a result, the planning aim is more often achieved, especially for large tumors.

show abstract

Feasibility of electronic brachytherapy in cervix cancer–A dosimetric comparison of different brachytherapy techniques

Cited by 2 publications

References 32 publications

Electronic brachytherapy for gynecological cancers — a systematic review

Electronic brachytherapy for gynecological cancers — a systematic review

The impact of different treatment protocols on achieved radiation doses of high-dose-rate brachytherapy for locally advanced cervical cancer: a comparison between 2 fractions in 1 application and separate applications for each fraction

Contact Info

Product

Resources

About